MAY 12, 2020 8:43 PM PDT

Novel Drug Approved for Non-Small Cell Lung Cancer

WRITTEN BY: Nouran Amin

The US Food and Drug Administration (FDA) recently approved a therapeutic for treating metastatic non-small cell lung cancer (NSCLC). The therapeutic called ‘Tabrecta™ (capmatinib, formerly INC280)’ is an oral MET inhibitor for patients with a METex14 mutation in their tumors.

Learn more about non-small cell lung cancer (NSCLC):

 

 

“Non-small cell lung cancer is a complex disease, with many different possible mutations that may encourage the cancer’s growth,” said Juergen Wolf, MD, from the Center for Integrated Oncology, University Hospital Cologne and lead investigator of the GEOMETRY study. “MET exon 14 skipping is a known oncogenic driver. With today’s decision by the FDA, we can now test for and treat this challenging form of lung cancer with targeted therapy, offering new hope for patients with NSCLC harboring this type of mutation.”

The approval of Trabecta is based on findings from the pivotal GEOMETRY mono-1 Phase II clinical trial. The most common side-effects noted were peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.

“Today, and especially during these difficult times, we are incredibly proud that Tabrecta is the first treatment approved by the FDA specifically to treat patients diagnosed with this aggressive NSCLC associated with METex14,” said Susanne Schaffert, PhD, President, Novartis Oncology. “In our quest to reimagine medicine, we have worked tirelessly over the past decades to advance the understanding and treatment of NSCLC, striving to make a difference in patients’ lives, one mutation at a time. We thank all the physicians, patients and families involved in the Tabrecta clinical trials, and we remain committed to advancing innovative solutions for the patients we work to serve.”

Source: Novartis

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JUL 20, 2022
Neuroscience
Stress Transmitter Wakes Up the Sleeping Brain Over 100 Times Per Night
JUL 20, 2022
Stress Transmitter Wakes Up the Sleeping Brain Over 100 Times Per Night
A study published in Nature Neuroscience reported that the stress hormone and transmitter noradrenaline wakes up the hum ...
AUG 07, 2022
Neuroscience
Physiotherapy Technique Significantly Improves Chronic Back Pain
AUG 07, 2022
Physiotherapy Technique Significantly Improves Chronic Back Pain
Sensorimotor retraining significantly improves pain intensity in chronic low back pain. The corresponding study was publ ...
AUG 17, 2022
Drug Discovery & Development
A new software platform to help with drug discovery efficiency
AUG 17, 2022
A new software platform to help with drug discovery efficiency
The process of drug discovery and development is expensive. A recent report from the Journal of the American M ...
AUG 30, 2022
Clinical & Molecular DX
Caffeine Metabolite Could Slow Progression of Nearsightedness in Children
AUG 30, 2022
Caffeine Metabolite Could Slow Progression of Nearsightedness in Children
Myopia, also known as nearsightedness, is a common vision condition in which objects far away appear blurry. Myopia occu ...
SEP 11, 2022
Plants & Animals
Potential Treatment for Chagas Disease
SEP 11, 2022
Potential Treatment for Chagas Disease
Chagas disease is a condition caused by a parasitic infection; specifically, the parasite Trypanosoma cruzi (T. cruzi), ...
SEP 11, 2022
Drug Discovery & Development
Effects of Ketamine in Mice Depend on Sex of Human Experimenter
SEP 11, 2022
Effects of Ketamine in Mice Depend on Sex of Human Experimenter
Researchers found that mice more consistently experience antidepressant effects from ketamine when administered by men a ...
Loading Comments...